FUTURE. VACCINES. FIRST. 

We are a privately-owned biotechnology company developing novel vaccines for infectious diseases at a rapid scale using our proprietary platform technology, synVAX.

  • BROAD SPECTRUM

    Provides broad protection against bacterial and viral infection through antibody and cell mediated immune responses

  • SINGLE VACCINATION

    Highly immunogenic: one vaccination is required to stimulate long lasting vaccine-induced immunity

  • SCALABLE & FAST PRODUCTION

    From vaccine concept design to proof of concept animal data in under 10 months, commencement of GMP manufacture in under 12 months

The speed of development is a key feature of our technology.

We have developed five vaccines in under a year. VAXMED uses complex computer algorithms to design and develop highly effective vaccines and a state-of-the-art production process. Our vaccines are fully synthetic and designed to provide long-lasting immunity in a single immunisation.

VAXMED is an Australian biotechnology company designing, developing and manufacturing next-generation vaccines for unmet medical needs.  With our new technology enabling us to make safe and effective vaccines in record time and on an unprecedented scale. 

About Us

synVAX Vaccines

Combining the best biotechnology processes in a new vaccine technology

Structure: Double-stranded DNA encapsulated in viral proteins

Design: Fully in-silico, proprietary algorithms, plug-and-play

Manufacture: Rapid assembly of synthetic DNA fragments

Dosage: Single dose only, no boosting, avoiding vaccination fatigue and side effects

Efficacy: Strong, lasting B and T-cell responses

Formulation: No additives, preservatives, lipids, adjuvants

Safety: Key features of an old vaccine (VV) with safety data in 300m+, exceeding the safety of MVA

Payload: ~30kb = as part of a single DNA molecule, broad-spectrum vaccine ↑ epitopes = ↑ protection against mutations

Logistics: Thermo-stability as a liquid at room temperature

CapEx: Single, high-yield production process and infrastructure for all vaccines

Meet the Founders

  • Paul is the inventor of Vaxmed’s synVAX platform vaccine delivery technology and the vaccines in development. He has decades of experience managing vaccine development programs expertise in the areas of antigen design and discovery, proof of concept studies in animal models, GLP preclinical and toxicology studies, process development and cGMP manufacturing, regulatory affairs and first-in-man studies concerning live viral vectored vaccines.

  • Jurgen has over 30 years’ experience as a senior manager in the international life sciences industry, as well as in Australian public and private companies and research centres. He has worked in Munich, Copenhagen, Sydney, Brisbane and Adelaide in senior executive roles including serving on boards as chairman and director and CEO of companies.

    He has a strong track record bringing research outcomes to market, including building and financing companies and listing on stock exchanges as lead investor. He has served as executive in the vaccine industry and is leading developments in infectious disease and oncology companies.

VAXMED Pipeline

2nd Generation SARs-CoV-2 Vaccine

Designed to protect against current and future VOC

A major cause of lower respiratory tract infections in children and elderly worldwide every year

Respiratory Syncytial Virus (RSV)

Simultaneously protecting from Influenza A and B infections, all seasonal strains

Universal influenza vaccine

Dual Staphylococcus and Pseudomonas Vaccine

Chronic lung infection in cystic fibrosis patients, burn and soft tissue infections, preventative vaccination prior to elective surgery, additional military market

A veterinary vaccine for the highly contagious infection, decimating the pork industry in Asia and is a major problem in Europe and Africa

African swine fever (AFS) Vaccine

The ‘empty’ vaccine for insertion of disease-specific antigens for rapid development of target vaccines. synVAXprotects against mpox

synVAX

synVAX cell substrate is a single-cell suspension culture, in a chemically defined growth medium, for stirred tank or fix-bed bioreactors, expanding at a rate of 1 to 10 within 2 to 3 days

Cell Substrate and manufacturing

Our vaccines give broad-spectrum coverage against multiple virus strains or infectious diseases. All are high-value and unique vaccines with large global markets.

Common to many other vaccines is the requirement for two injections, several weeks apart, to ensure efficacy. Our single vaccination is designed to be effective after only two weeks, providing long-lasting protection.

Why we’re different

The speed of vaccine design and manufacturing is a key differentiator of VAXMED’s technology. Our proprietary cell line, universal manufacturing technology and synVAX vector technology make our manufacturing proposition scalable. Our production technology is designed to produce 100s of millions of doses from each batch run in a matter of weeks.

Unlike most other vaccines, VAXMED vaccines do not require consistent cold storage and temperature control from manufacture through to the point of use. Our vaccines can be stored at room temperature for at least one week, and when freeze-dried, for many years.

Our vaccine technology has been independently evaluated by leading global vaccine experts, both in industry and academia, and we have received the written endorsement of both our technology and vaccine candidates.

Our Partners

Our network of established and competent partners to drive vaccine development and manufacturing

Get In Touch

We’d love to hear from you. Find out more about why synVAX is the next-generation solution for developing vaccines to combat current and potential future outbreaks.